StockUS listing USBLRXNASDAQHealthcareEarnings Deterioration

BioLineRx Ltd(BLRX) Stock Analysis | Healthcare

USD --+0.00%
Reward41Moderate
Risk60Medium-High
75%Data
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 4.80M
Reward Ratingⓘ41 Moderate reward assessment · 75% data coverage
Bottom 10% of stocksView factors
Risk Ratingⓘ60 Medium-High risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on BLRX to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is BioLineRx Ltd?

, a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases.

AI Brief Pro

The brief on BioLineRx Ltd

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is BioLineRx Ltd?

, a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 4.80M.

Financial Highlights

Investment Breakdown

Growth
Growth trend is developing — watch for revenue consistency over upcoming quarters.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Moderate volatility with meaningful macro and earnings sensitivity.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (41)
Company Information
SectorHealthcare
IndustryBiotechnology
Beta0.789
Insider Activity
12M windowNo data
No insider activity data available for this ticker.